Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleuc...
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Acquire Media Monitor
Safety findings consistent with prior studies with no reports of cytokine release syndrome, tumor flare reactions, immune effector cell-associated neurotoxicity syndrome, and organ rejection, Biologics license application (BLA) under priority review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2025 If approved, tabelecleucel would be the first approved allogeneic , off-the-shelf, T- cell therapy in U.S. and only FDA-approved treatment for R/R EBV+ PTLD a n ultra- rare, acute, and potentially deadly hematologic malignancy that occurs after life saving transplantation PARSIPPANY, N.J. Dec. 7, 2024 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc., today announced updated results presented at the 66th American Society of Hematology (ASH) Annual Meeting of the pivotal Phase 3 ALLELE study of tabelecleucel in adults and children two years of age and older with relapsed or refractory (R/R) EBV+ PTLD followi
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceBusiness Wire
- Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
ATRA
Earnings
- 11/12/24 - Beat
ATRA
Sec Filings
- 12/23/24 - Form 8-K
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- ATRA's page on the SEC website